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S_r The effect of insulhn-like growth factor II (IGF-II) on tumour development in the mouse mammary
gland was studied To promote exra IGF-II on in the mammary gland, sheep P-Lactoglobulin
regulatory elements were attached to the coding regions of the mouse Ig-2 gene and injected into the
pronucei of mouse zygotes. Mammary tumours deveoped m each of the four in e t ines of mice which
expressed tansgne IGF-II in the gland Tumours from two of the lnes grew aft transantation to both
male and fenale hosts. Primary tumours contained strmal and epithelial reg s, but the tumours were
domated by mammary after transplantatkin. The tumours ssed high level of Igf-2
mRNA transcribed from the integrat transgenes.
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There is no direct evidence that either insulin or the insulin-
like growth factors (IGFs) contribute to cancer growth in the
human breast (reviewed by Yee, 1992; Callahan and
Salomon, 1993). Genetic evidence is also lacking because the
IGF genes and the IGF receptor genes are not frequently
amplified in mammary carcnomas and the two major
familial susceptibility genes map elswhere (Hall et al., 1990;
Berns et al., 1992; Milao et al., 1992; Hebert et al., 1994;
Wooster et al., 1994). However there is accumulating
evidence that IGF-H can promote the growth of human
breast cacer cell lines in culture and in xenografs (e.g.
Brunner et al., 1992), and that part of this action is mediated
through the type 1 IGF receptor (Peyrat and Bo te,
1992). This cirumstantial evidence suggested the present ex-
perimental study.
The purpose was to find out if enhanced IGF-H expression
in the mouse mammary gland caused tumours. We report
that this is the case for tansgenic mice, in which IGF-H
expression is controlled by the sheep -lactoglobulin regu-
latory elements. Although IGF-H is found at low concentra-
tion in the normal milk of humans, cows and rats (Francis et
al., 1988; Donovan et al., 1991a,b; Breier et al., 1993), it now
joins a growing list of oncogene products and growth factors
whose excess leads to tumour formation in the mouse breast
(reviwed by Wang et al., 1994; Webster and Muller, 1994).
Mateals and mthod
Transgene construction
The Igf-2 locus and the constructs are illustrated in Figure 1.
Sheep P-lactoglobulin (BLG) promoter sequences were sub-
cloned using a Sall site, located approximately 4 kb 5' of the
tanscript initiation site, and a XhoI site (formerly a Pvull
site, converted using an oligonucleotide linker) within the
BLG untranslated leader sequences (Ali and Clark, 1988;
Harris et al., 1988; Whitelaw et al., 1992). The Sall-XhoI
fragment was ligated at a 5' Sall site within a genomic
subclone encompassing all three I-2 coding exons (Ward et
al., 1994), derived from a largr fragment (Rotwein and HalL
1990). Before pronuclear microinjection, the BLG/IgI-2 gene
fusion was purified from pUC19 vector sequences as an
approximately 8 kb EcoRI fragment, utilising sites located
about 3 kb 5' of the BLG transcript initiation site and
immediately 3' of Igf-2 genomic sequences. A probe for
detecting transgenc mice on Souther blots consist of a
692bp XbaI to KpnI fragment containing part of exon 6
from the genomic clone (Rotwein and Hal, 1990).
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Fugwe 1 Transgene design. The geomic Ig-2 locus (Rotwein
and Hall 1990) is displayed with transcrpt nation sites (filled
arrows), cxons (open boxes, numbered 1 to 6), and first in-a
anslaonal start (open tnangie) and stop (filed triange) dons
ed. The tansgene cons t compises approximatey 3 kb
of the 5' promoter sequence from the sheeP-lactog in gene
(BLG) joied with the three Igf-2 coding cxons, to form a trans-
criptional fusion (stippled rectanges mark the BLG part). The
region spannig the BLGII-2 sequenc juncti subconed to
generate a probe consuc for use in ribonucleas potction
assays, has been magnified Transcript mination sites are given
for both the BLG gene promoter (filed arrow), and the
bacteriophage SP6 polymerase promoter (open arrow) used to
synthesi antisense RNA probes. Regioins of probes protected
from RNAse degradation following hybridisation with endo-
genous (125 bp) and tansgen (183 bp) tansipts are also
shown. Tbe probe used to detect the tansgenes in DNA on
Southern blots is shown at the top, togetr with the XbaI
fragent from the endogenous (approximatdy 1.8 kb) and trans-
gene locus, the latter fragment varying in size with the integration
site.
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Ribonuclease protection assays
A probe construct was generated by transferring sequences
spanning the BLGlIgf-2 transgene cloning junction into the
pGEM-4Z vector. The 224 bp fragment extended from an
SphI site, 45 bp upstream of the BLG transcript initiation
site, to a HincII site within the first Igf-2 coding exon (exon
4), and it was inserted at the same sites in pGEM-4Z. This
allowed the generation of a 267 nucleotide antisense RNA
probe with SP6 RNA polymerase, following linearisation of
the probe construct with HindlII. The probe was uniformly
labelled by incorporation of 3P during the polymerase reac-
tion (Melton et al., 1984), and RNAse protection assays were
performed on samples of total RNA as previously described
(Ward et al., 1994). The fragments protected from ribo-
nuclease degradation were either 183 nucleotides (transgene)
or 125 nucleotides long (endogenous). In all cases RNA
integrity and loading was judged with a second probe which
reacts with transcripts of the housekeeping gene encoding
mouse glyceraldehyde 3-phosphate dehydrogenase (mGAP;
Rathjen et al., 1990). Also included were controls with cell-
ular RNA from NIH-3T3 cells (as a source of endogenous
Igf-2 transcripts), or with yeast tRNA. The sizes of protected
fragments were checked using dideoxynucleotide sequence
ladders (not shown).
Transgenesis and breeding
The transgene was injected into one pronucleus of zygotes
which were the product of a cross between two F, C57BL6/
CBA parents, using standard techniques (Hogan et al., 1986;
Allen et al., 1987). Thirteen percent of the young contained
the transgene as judged by Southern blots of tail tip DNA at
4 weeks old. Amongst these eight transgenic founders, two
did not transmit the transgene, a third had young which did
not express the transgene and a fourth line died out. In the
four breeding lines, the transgene behaved as a single
Mendelian factor, with 3-10 copies of the transgene integ-
rated into the heterozygous mice (Laura and Leroy 10 copies,
Lesley 3 copies, Lorna 5 copies). These four founder trans-
genic mice gave rise to permanent lines, and the lines were
maintained by breeding transgene heterozygotes by F, C57-
BL6/CBA partners. Female transgene heterozygotes were
poor mothers and there was excess mortality of their off-
spring during the lactation period (Fisher et al., unpub-
lished). Each line was usually maintained by male transmiss-
ion or by using normal mothers to wet nurse the offspring of
transgenic mothers.
Tumour incidence and transplantation
The females were placed with normal F, C57BL6/CBA males
and the birth of each litter was recorded. The control mice
were also transgenic and they were female founders and the
daughters of male founders. These control transgenics were
made and maintained on exactly the same genetic back-
ground as the experimental mice. The transgene constructs in
the control mice consisted of the mouse Igf-2 regulatory
elements attached to a firefly luciferase reporter gene and this
gene was hardly expressed in the mammary gland (unpub-
lished).
The mammary gland tumours were visible as external
lumps, and they could also be found by palpation at early
stages of their growth. When the lumps reached approx-
imately 1 cm in diameter, the tumours were removed under
Avertin anaesthesia. They were cut into 5 mm diameter
lumps in solution A of Dulbecco and Vogt (1954), and these
were transferred beneath the dorsal skin of F, C57BL6 CBA
hosts. To find out if the endocrinological changes of preg-
nancy altered tumour growth, some female hosts were
allowed to mate. In this case the virgin and mating female
hosts each received a tumour transplant weighing approx-
imately 0.041 g.
Histology
Whole mounts of the fourth and fifth mammary gland were
prepared (Edwards et al., 1988). In addition. mammary
glands and tumours were fixed in 10% formal saline or
Bouin's fixative, sectioned at 8 lim after wax embedding and
stained with haematoxylin and eosin. Tumours were also
fixed, stained with osmium tetroxide, sectioned at 1 tim and
stained with hot toluidine blue as described previously (Flet-
cher et al., 1978).
Plasma insulin-like grow thfactor assayss
The IGFs were separated from the binding proteins by acid
gel chromatography before immunoassay of IGF-I and IGF-
II (Hill, 1990). Human recombinant IGF-1 or IGF-II were
used to construct standard curves (UBI, Lake Placid, NY,
USA). About 10% of the IGF-II immunoreactivity eluted
at<6- 8 kDa. Each IGF-I and IGF-II plasma sample was
measured within two separate assays. For IGF-I, the intra-
and interassay coefficients of variation were 10% and 12%
respectively, while the sensitivity was 0.4 ng ml-'. The cross-
reactivity of IGF-II in the assay was less than 1%. For
IGF-II, the intra- and interassay coefficients of variation
were 8% and 13% respectively. and the minimum level of
detection was 5 ng ml-'. The cross-reactivity with IGF-I in
the assay was less than 1%.
Results
Breeding history and tumour incidence
Mice from each of the four lines which expressed excess Igf-2
mRNA from the transgene in the mammary gland developed
mammary tumours (Table I). These and subsequent tumours
were found during routine breeding of females which were
heterozygous for the transgene integration site. The tumours
occurred in both female founder mice (Laura and Lorna),
and in female descendants of the male founders (Leroy and
Lesley).
No mammary tumours were found in control mice. The
control group for the P-lactoglobulin: IGF-II transgenic
founders and their descendants consisted of nine other trans-
genic founders containing a different construct which did not
express in the mammary gland (see Materials and methods).
The number of litters and the mean litter interval of these
Table I Incidence of mammary tumours
Total Age (months) Number ofnew twnoursfound in a particular
no. of whenfirst age interval (months)
Transgenic line tumours detected 0-2 2-4 4-6 6-8 8-12
Laura 3 5, 5, 16 O017 0/1 7 213 0 5 ND
Leroy 6 4, 7, 8, 8, 8, 9 0/49 1/35 0,24 4 17 ND
Lesley 6 6, 8, 9, 10, 11, 12 0/37 0/37 1,27 1 6 4 5
Lorna 2 6, 11 0/31 0/31 1,27 0 10 19
The numberofnew tumoursfound in aparticularage interval isexpressed as a ratio ofthe numberofnew
tumours detected in that interval over the total numbeF oftransgenic females at that age. ND means that
observations on transgenic mice without tumours did not continue up to that age and therefore a tumour
incidence ratio can not be given. No mammary tumours were found in control transgenic lines which
contained different constructs.IGl4 ard mammary tumours
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transgemc controls was similar to the experimentals (3.3
weeks), and the mean age was 10 months at the end of
detailed observations of these controls.
Tumour incidence was scored as the number of new
tumours which were detected in the transgenic females over a
particular time interval, divided by the number of age-
matched transgenic females which did not develop tumours
(Table I). In this table, the total number of mice decreases
with age because many were used for other experiments.
Transgene expression and tumour histologv
There were high levels of the transgene Igf-2 transcripts in
the primary tumours found in non-lactating females (Figure
2). These levels were similar to those found in the normal
lactating mammary gland of these transgenic lines (day 10-12
of lactation) and they were maintained in the transplanted
tumours. as judged by the reference mGAP and endogenous
Igf-2 transcripts (not shown).
Igf-2 gene expression is subject to extensive post-
transcriptional control. and there is no simple relationship
between mRNA and protein abundance in cell culture,
human tumours or the normal mouse embryo (e.g. Hasel-
bacher et al.. 1987: Nielsen 1992; Newell et al.. 1994). The
expression of Igf-2 mRNA in the tumours increased the
circulating levels of IGF-II protein in plasma when compared
with normal virgin females or virgin transgenic females of the
same lines (Fisher et al., unpublished). The extent of the
increase was very variable. Three tumour-beanrng mice of the
Laura line were studied, and the IGF-II levels were 185, 454,
and 3920 ng mi-'. One tumour bearing Lorna mouse had
185ngml-' and a similar Lesley mouse had 386ngmVl.
Virgin transgenic mice had mean levels of 33 ng ml-'. slightly
higher than those found in normal mice (DaCosta et al..
1994).
The tumours were classified as mammary carcinoma type
B (Squartini and Pingitore, 1994). The primary tumours
contained epithelial and stromal elements but the stromal
elements were reduced on transplantation.
Tumour distribution and transplantation
The tumours were first detected as single lumps but they were
found in several glands at autopsy. When the initial tumours
were surgically removed. tumours subsequently developed in
other glands. Such a multigland distribution is also common
in mice expressing extra cyclin Dl in the gland and it con-
trasts with most spontaneous mammary adenocarcinomas
which develop in single glands (Wang et al.. 1994).
It is important to establish that growths with a neoplastic
appearance can grow progressively after transplantation.
Three lines with tumours were tested and at least one tumour
was transplanted to at least four normal female and one
normal male recipient. The Laura and Lesley tumours grew
progressively in each host, while the single Lorna tumour was
not transplantable and the Leroy tumour was not tested.
The primary tumours had first been detected in females
which had carried several litters. It was decided to find out if
the hormonal changes of successive pregnancies had any
effect on tumour growth. Equal volumes of one primary
tumour line were transplanted to mating and virgin females
(Laura line). Four months after transfer the animals were
killed. The final mean tumour weight was a quarter higher in
the mating females, which all carried litters (Table II). This
weight increase was not significant because of the high stan-
dard deviation in both sets of recipients.
Discussion
Local IGF-II action in mammary carcinomaformation
The pattern of tumour occurrence strongly supports the con-
clusion that these lesions are an effect of the transgene. With
each of the four separate lines suffering tumours. the
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Fgre 2 Transgene expression in tumours. A probe protection
assay of IGF-II transgene expression in mammary carcinomas
from each of the three transgenic lines which developed tumours.
The position of the transgene transcript is marked (Trans). The
position of the endogenous Igf-2 mRNA is shown (Endo). The
use of a probe to the cellular RNA which codes for mouse
glyceraldehyde 3-phosphate dehydrogenase (mGAP) demonstrates
that Igf-2 mRNA expression is excessive in the tumours when
compared with NIH 3T3 cells in culture. The probes do not react
with any sequences in transfer RNA (tRNA). The mobility of
probes before RNAse treatment is shown in the left track (Pro-
bes).
Table II Effect of host type on tumour growth (transplantation)
Take Mean weight
Host tipe incidence in g ( s.d.)
Female.virgin 10 10 0.917 ( 1.1)
Female, mating 10 10 1.216 ( 1.2)
Similar size fragnents from a tumour in the Laura line were
transplanted to normal hosts and the recipients were killed 4 months
after transplantation. The mean number oflitters carried by the mating
females was 2.9 (range 1 -4) with a mean litter interval of 5.5 weeks.
tumongenic effect is clearly integration site independent and
must be a consequence of IGF-II expression. A survey of the
mammary gland wet weight, lipid content and histology in
these four lines has shown that there are no gross changes in
the virgin female gland at around 3 months old (Fisher et al.,
unpublished). A detailed analysis of tumour incidence awaits
further work but it is already clear that mammary carcinoma
development is slow when compared with some transgenic
lines which overexpress oncogene products in the mammary
gland (see Table I reviewed in Webster and Muller, 1994).
However, the tumours appear much faster than those which
develop after extra expression of cyclin Dl in this site (Wang
et al., 1994). Some other transgenic mouse lines with excess
IGF-II in adults also develop tumours: hepatocellular and
other carcinomas form in the second year of life, when extra
IGF-II is expressed from a major urinary protein (MUP)
promoter in the liver (Rogler et al.. 1994).
All four lines of transgenic mice used in the present study
had more IGF-I1 protein in the plasma than normal mice
(Fisher et al., unpublished), and the circulating growth factor
might increase the incidence of mammary tumours. However,
high circulating IGF-II levels are unlikely to be the
immediate cause of the tumours observed in the present
study because much higher levels are found in other trans-
genes (Rogler et al.. 1994), and these do not increase the
incidence of mammary tumours in the first year of life. It is
therefore probable that it is the local high expression of
IGF-II in the mammary gland which accelerates tumour
formation.
9
11910 P Bates et
112q
Twnow histology
The tumours were classified as mammary carcinoma type B
(Squartini and Pingitore, 1994). The 3-dimensional architec-
ture of the mouse mammary gland is regulated by the mesen-
chyme during development, while the type of cytodiffer-
entiation of the epithelium is determined by its embryonic
origin (e.g. Sakaka et al., 1976). It follows that the disor-
ganised architecture of a tumour could be caused by a
change of either partner in this interaction. Although all
primary tumours displayed excess growth ofboth the stromal
and epithelial parts of the gland, it was the epithelial
elements which predominated after transplantation. For this
reason, we believe that the important change was in the
epithelial cells.
Transgene expression andhost type
Although most of the lines first developed tumours after
mutliple pregnancies, the tumours could be readily trans-
planted into a variety of hosts which were not exposed to the
hormonal changes of pregnancy. The tumours continued to
express high levels of the transgene Ie-2 transcripts after
transplantation to non-pregnant hosts (not shown).
Excess IGF-II is not suficient to cause twnours in all organs
In the present work, excess IGF-H expression is shown to
contribute to tumour formation in the mouse mammary
gland: it is the experimental 'cause' of these tumours. In
contrast, excess IGF-II does not cause tumours in several
other organs. In adult mice, the cell numbers of the skin and
the uterus greatly increase when IGF-H is expressed in these
organs, but malignant tumours do not develop from these
disproportionate overgrowths (Ward et al., 1994). Further,
the extent of normal fetal tissue growth depends directly or
indirectly on the normal action ofthe endogenous Igf-2 genes
(DeChiara et al., 1990; Baker et al., 1993; Lee et al., 1993). It
is therefore unlikely that a single genetic change in IGF-ll
expression is sufficient in itself to make cells malignant, and
IGF-H presumably has ihis tumorigenic action in the mam-
mary gland because it increases the probability that other
genetic changes will occur in this organ.
Action ofIGF-II in tmnourformaton
The IGFs have long been known to maintain the health of
cells in culture and there is now a plausible mechanism for
this action (Conover et al., 1993; 1994). It is certainly possi-
ble that IGF-H's main function in tumour formation is to
increase cell survival (e.g. Biddle et al., 1988; Harrington et
al., 1994), and render cells competent to respond to other
growth factor signals: twin actions which are emphasised by
IGF-H expression in mouse pancreatic tumours (Christofori
et al., 1994; Christofori and Hanahan 1994). In mammary
tumorigenesis, an effect of IGF-H on cell survival might first
show up as inhibition of the apoptosis which accompanies
mammary gland regression during the 4 days after weaning
the young (Guenette et al., 1994). We have not yet measured
this feature.
It is also possible that the mammary gland is particularly
susceptible to IGF-II driven tumorigenesis because the gland
is a major organ of fat metabolism (Williamson, 1991), and
high carcass fat is often associated with frequent tumour
development in mice (e.g. Wolff et al., 1986; Wolff 1987).
IGF-l certainly has the capacity to alter lipid metabolism,
with a relatively high fat content retained in organs express-
ing high levels of IGF-H (DaCosta et al., 1994). Although
the anism by which high fat promotes tumour develop-
ment is not understood, it might be the metabolic actions of
IGF-II which account for its particular tumour promoting
effects in the mammary gland.
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